Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 11 Neoplasm Metastasis 4 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Ovarian Neoplasms 2 Recurrence 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms 1 Meningioma 1 Malignant Female Reproductive System Neoplasm 1 Lymphoma 1 Leukemia 1 Inflammatory Breast Neoplasms 1 Hemangiosarcoma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Ependymoma 1 Endometrial Neoplasms 1 Disease Progression 1 Disease 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Lobular 1 Breast Cancer With Brain Metastasis 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Gemcitabine 32 Cisplatin 31 durvalumab 15 pembrolizumab 14 Fluorouracil 13 Oxaliplatin 12 Leucovorin 12 Capecitabine 10 Bevacizumab 8 lenvatinib 7 Nivolumab 7 zanidatamab 4 Trastuzumab 4 S 1 (combination) 4 Paclitaxel 4 Liquid Biopsy 4 Irinotecan 4 Carboplatin 4 Albumin-Bound Paclitaxel 4 tremelimumab 3 tislelizumab 3 irinotecan sucrosofate 3 Injections 3 Folfox protocol 3 130-nm albumin-bound paclitaxel 3 toripalimab 2 pertuzumab 2 niraparib 2 ivosidenib 2 envafolimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Biliary Tract Neoplasms × neratinib × 1 year × Clear all

NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡